Search research articles
Contact Us
Filters
Showing results (31-40 of 43) with videos related to
Page
of 5
Sort By:
Pharmacoeconomics
|
October 28, 1999
Medical resource use and cost of venlafaxine or tricyclic antidepressant therapy. Following selective serotonin reuptake inhibitor therapy for depression
R I Griffiths, E M Sullivan, R G Frank, et al.
Bone Marrow Transplantation
|
September 1, 1993
Efficacy of immune globulin in preventing complications of bone marrow transplantation: a meta-analysis
E B Bass, N R Powe, S N Goodman, et al.
Pharmacoeconomics
|
March 8, 1998
Pharmacoeconomic analysis of 3 treatment strategies for cytomegalovirus retinitis in patients with AIDS
R I Griffiths, G C Bleecker, D A Jabs, et al.
Parkinsonism & Related Disorders
|
March 29, 2014
Daytime sleep in Parkinson's disease measured by episodes of immobility
K Kotschet, W Johnson, S McGregor, et al.
Helicobacter
|
May 1, 2001
Costs of managing Helicobacter pylori-infected ulcer patients after initial therapy
R I Griffiths, L Rabeneck, G Guzman, et al.
Health Care Financing Review
|
January 3, 1995
A review of the first year of Medicare coverage of erythropoietin
R I Griffiths, N R Powe, J Greer, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation
|
October 1, 1993
Medicare payment policy and recombinant erythropoietin prescribing for dialysis patients
N R Powe, R I Griffiths, G F Anderson, et al.
Journal of the American Society of Nephrology : JASN
|
January 1, 1994
Effect of recombinant erythropoietin on hospital admissions, readmissions, length of stay, and costs of dialysis patients
N R Powe, R I Griffiths, A J Watson, et al.
Infection Control and Hospital Epidemiology
|
November 4, 1998
Medical-resource use for suspected tuberculosis in a New York City hospital
R I Griffiths, C L Hyman, S I McFarlane, et al.
Kidney International
|
May 1, 1993
Early dosing practices and effectiveness of recombinant human erythropoietin
N R Powe, R I Griffiths, J W Greer, et al.
Page
of 5
Search research articles
Search
Showing results (31-40 of 43) with videos related to
Sort By:
Page
of 5
Pharmacoeconomics
|
October 28, 1999
Medical resource use and cost of venlafaxine or tricyclic antidepressant therapy. Following selective serotonin reuptake inhibitor therapy for depression
R I Griffiths, E M Sullivan, R G Frank, et al.
Bone Marrow Transplantation
|
September 1, 1993
Efficacy of immune globulin in preventing complications of bone marrow transplantation: a meta-analysis
E B Bass, N R Powe, S N Goodman, et al.
Pharmacoeconomics
|
March 8, 1998
Pharmacoeconomic analysis of 3 treatment strategies for cytomegalovirus retinitis in patients with AIDS
R I Griffiths, G C Bleecker, D A Jabs, et al.
Parkinsonism & Related Disorders
|
March 29, 2014
Daytime sleep in Parkinson's disease measured by episodes of immobility
K Kotschet, W Johnson, S McGregor, et al.
Helicobacter
|
May 1, 2001
Costs of managing Helicobacter pylori-infected ulcer patients after initial therapy
R I Griffiths, L Rabeneck, G Guzman, et al.
Health Care Financing Review
|
January 3, 1995
A review of the first year of Medicare coverage of erythropoietin
R I Griffiths, N R Powe, J Greer, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation
|
October 1, 1993
Medicare payment policy and recombinant erythropoietin prescribing for dialysis patients
N R Powe, R I Griffiths, G F Anderson, et al.
Journal of the American Society of Nephrology : JASN
|
January 1, 1994
Effect of recombinant erythropoietin on hospital admissions, readmissions, length of stay, and costs of dialysis patients
N R Powe, R I Griffiths, A J Watson, et al.
Infection Control and Hospital Epidemiology
|
November 4, 1998
Medical-resource use for suspected tuberculosis in a New York City hospital
R I Griffiths, C L Hyman, S I McFarlane, et al.
Kidney International
|
May 1, 1993
Early dosing practices and effectiveness of recombinant human erythropoietin
N R Powe, R I Griffiths, J W Greer, et al.
Page
of 5